A recent study revealed promising results for the highly differentiated 1L EGFR PACC treatment, showing a preliminary systemic activity with an 80% Overall Response Rate (ORR) and a 100% intracranial ORR. These results were observed in patients with active brain metastases, indicating a potentially effective treatment option for this group of patients.